Related Experiment Video
Updated: Apr 17, 2026

Implantation Protocol of the Foldable Capsular Vitreous Body for Complex Vitreoretinal Surgery
Published on: April 14, 2026
Intravitreal foscarnet is an effective adjunct after systemic therapy failure in pediatric antiviral-resistant
Iden Amiri1, Pooja Shah1, Mohammad Soleimani1
1University of North Carolina-Chapel Hill, Department of Ophthalmology, United States of America.
Abstract:
This report describes the case of a school-aged male child with T-cell acute lymphoblastic leukemia who developed cytomegalovirus retinitis despite systemic antiviral therapy. The patient had a history of cytomegalovirus viremia that improved with intravenous foscarnet and oral maribavir; however, routine ophthalmic screening revealed new retinal whitening and hemorrhages in the right eye. Anterior chamber paracentesis confirmed intraocular cytomegalovirus DNA. Although systemic viral loads declined, the retinal lesions progressed toward the macula, prompting initiation of intravitreal foscarnet. Treatment was initiated with a 1.2 mg/0.05 mL injection under anesthesia, followed by 2.4 mg/0.1 mL injections administered twice weekly at the clinic. The regimen was well tolerated and resulted in stabilization and regression of retinitis without central involvement, with fundus photography demonstrating fading whitening and vascular sclerosis.This case highlights the importance of close ophthalmic monitoring in immunosuppressed pediatric patients with cytomegalovirus viremia and emphasizes intravitreal foscarnet as an effective adjunct when systemic therapy fails. Furthermore, it demonstrates the feasibility of administering multiple intravitreal injections in the pediatric population, underscoring the role of local antiviral delivery in preserving vision in cases of antiviral-resistant cytomegalovirus retinitis.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Cytomegalovirus Disease
Angle Closure Glaucoma: Treatment
Antifungal Agents
Ophthalmic Drug Delivery Systems
Treatment Resistent Cancers

